Patients with multimorbidities have shorter life expectancy and their clinical management is more complex and expensive for healthcare systems currently focused on treating single diseases. Given that age is the major risk factor for multimorbidity, the challenge of treating these patients will only increase in coming years. Here, we review the case for targeting the core processes that drive the ageing phenotype as a novel pharmaceutical approach to multimorbidity. There is growing evidence that targeting ageing mechanisms can reduce or delay age-related diseases in animal models, and the first reports of clinical trials are now appearing. Although these trials currently focus on repurposed drugs, we propose several novel targets that would more specifically target ageing processes and thereby reduce multimorbidity and polypharmacy in future generations.

对于目前专注于治疗单一疾病的医疗保健系统而言，患有多种疾病的患者预期寿命较短，其临床管理更为复杂和昂贵。鉴于年龄是多发病的主要风险因素，治疗这些患者的挑战在未来几年只会增加。在这里，我们回顾了将驱动衰老表型的核心过程作为治疗多发病的新药物方法的案例。越来越多的证据表明，针对衰老机制可以减少或延缓动物模型中与年龄相关的疾病，临床试验的首批报告正在出现。尽管这些试验目前集中在重新利用药物，